DepYmed

company

About

DepYmed Inc.is a disease therapeutic development company.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$100K
Industries
Biotechnology
Founded date
Jan 1, 2014
Number Of Employee
11 - 50
Operating Status
Active

DepYmed Inc., is a New York based cancer and rare disease therapeutic development company. DepYmed is currently developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome. In addition to PTP1B inhibitors, DepYmed has developed a portfolio of novel small molecules with copper chelating properties which can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. DepYmed continues to develop the next generation of more potent PTP1B inhibitors as well as selective copper chelators which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory. DepYmed continues to explore additional indications that may benefit from using PTP1B inhibitors and selective copper chelators as therapeutic agents.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$100K
DepYmed has raised a total of $100K in funding over 2 rounds. Their latest funding was raised on Dec 22, 2015 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 22, 2015 Grant $100K 2 the Long Island Emerging technologies Fund (LIETF)
Accelerate Long Island
Detail

Investors

Number of Lead Investors
Number of Investors
2
2
DepYmed is funded by 2 investors. the Long Island Emerging technologies Fund (LIETF) and Accelerate Long Island are the most recent investors.
Investor Name Lead Investor Funding Round
the Long Island Emerging technologies Fund (LIETF) Yes Grant
Accelerate Long Island Yes Grant